Equity Profile

ABBV

AbbVie Inc.

Health CareBiotechnology$438.2B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well AbbVie is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABBV Q2-2026 Earnings Preview

Context

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases. With a market cap of $438 billion, it plays a significant role in the health care sector, particularly in biotechnology, addressing major health challenges through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q1 2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for AbbVie are mixed, with some analysts anticipating continued strong performance while others are cautious due to recent revenue fluctuations.

Bull Case

The optimistic view hinges on AbbVie continuing its trend of beating EPS estimates, which could signal robust demand for its products and effective cost management.

Bear Case

Conversely, concerns about potential revenue declines or increased competition in the biotechnology space could lead to a disappointing earnings report.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given AbbVie's history of beating EPS estimates, this figure will be crucial for investor confidence and stock performance.

How is AbbVie addressing competition in the biotechnology sector?

Understanding AbbVie's strategy against competitors will provide insights into its future growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating AbbVie's ability to outperform due to its strong pipeline and recent product launches.

Supporting Evidence

AbbVie has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent product developments could drive unexpected revenue growth not reflected in current estimates.

Key Risk

If AbbVie reports an EPS significantly above $2.70, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around AbbVie's ability to maintain profitability in a competitive environment.

Bull Confirmed If

An EPS of $2.70 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $2.60 could indicate underlying issues with product sales or market share.

Pre-Earnings Positioning

Options Market

Implied Move

±5.85%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±5.8% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

23.2%

Calls (444K)P/C Ratio: 0.73Puts (307K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests the stock could rise by around 1.78%, confirming strong demand and management effectiveness.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement as investors reassess.

Miss

A miss on EPS could lead to a decline of about 0.15%, reflecting disappointment and potential concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on profitability.
3Discussion on competitive pressures and how AbbVie plans to address them.
4Management's outlook on future revenue growth and market expansion.
5Any changes in guidance or expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well AbbVie is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABBV Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q1 2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for AbbVie are mixed, with some analysts anticipating continued strong performance while others are cautious due to recent revenue fluctuations.

Bull Case

The optimistic view hinges on AbbVie continuing its trend of beating EPS estimates, which could signal robust demand for its products and effective cost management.

Bear Case

Conversely, concerns about potential revenue declines or increased competition in the biotechnology space could lead to a disappointing earnings report.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given AbbVie's history of beating EPS estimates, this figure will be crucial for investor confidence and stock performance.

How is AbbVie addressing competition in the biotechnology sector?

Understanding AbbVie's strategy against competitors will provide insights into its future growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating AbbVie's ability to outperform due to its strong pipeline and recent product launches.

Supporting Evidence

AbbVie has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent product developments could drive unexpected revenue growth not reflected in current estimates.

Key Risk

If AbbVie reports an EPS significantly above $2.70, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around AbbVie's ability to maintain profitability in a competitive environment.

Bull Confirmed If

An EPS of $2.70 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $2.60 could indicate underlying issues with product sales or market share.

Pre-Earnings Positioning

Options Market

Implied Move

±5.85%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±5.8% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

23.2%

Calls (444K)P/C Ratio: 0.73Puts (307K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests the stock could rise by around 1.78%, confirming strong demand and management effectiveness.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement as investors reassess.

Miss

A miss on EPS could lead to a decline of about 0.15%, reflecting disappointment and potential concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on profitability.
3Discussion on competitive pressures and how AbbVie plans to address them.
4Management's outlook on future revenue growth and market expansion.
5Any changes in guidance or expectations for the next quarter.